Hailshadow
- Legend Biotech (NASDAQ:LEGN) announced Friday that Carvykti, the CAR-T cell therapy that the company commercializes with Johnson & Johnson (NYSE:JNJ), met the primary endpoint in a Phase 3 trial for patients with multiple myeloma.
- The CARTITUDE-4 trial involved adults with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy. The study tested Carvykti against standard MM treatment regimens called PVd and DPd.
- CARTITUDE-4 met the primary endpoint indicating a statistically significant improvement in progression-free survival (PFS), the company said, adding that investigators will continue to assess patients for primary and secondary endpoints.
- Legend (LEGN) expects to submit findings at a future medical meeting and discuss results with authorities for regulatory submissions.
- The company announced $55M net sales for Carvykti for the December quarter.